Eli Lilly’s existing October 2024 agreement with Peptron covers only a non-exclusive, internal R&D evaluation of the SmartDepot ultrasonic spray-dried PLGA microsphere platform for selected peptides, with any commercial license explicitly optional and not guaranteed. The evaluation window, extended to a maximum of 24 months, runs through roughly October 2026, yet no binding technology-transfer or commercialization deal has been disclosed after nearly 20 months. Lilly’s parallel expansions of lipid-based injectable partnerships with Camurus for overlapping peptide areas have further reduced urgency around SmartDepot. With just over two months remaining until the market resolution date and no recent announcements signaling a shift to full licensing, traders assign an 87.5% implied probability to “No.”
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$11,138 Vol.
$11,138 Vol.
Oct 7, 2026
$11,138 Vol.
$11,138 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 agreement with Peptron covers only a non-exclusive, internal R&D evaluation of the SmartDepot ultrasonic spray-dried PLGA microsphere platform for selected peptides, with any commercial license explicitly optional and not guaranteed. The evaluation window, extended to a maximum of 24 months, runs through roughly October 2026, yet no binding technology-transfer or commercialization deal has been disclosed after nearly 20 months. Lilly’s parallel expansions of lipid-based injectable partnerships with Camurus for overlapping peptide areas have further reduced urgency around SmartDepot. With just over two months remaining until the market resolution date and no recent announcements signaling a shift to full licensing, traders assign an 87.5% implied probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,138End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 agreement with Peptron covers only a non-exclusive, internal R&D evaluation of the SmartDepot ultrasonic spray-dried PLGA microsphere platform for selected peptides, with any commercial license explicitly optional and not guaranteed. The evaluation window, extended to a maximum of 24 months, runs through roughly October 2026, yet no binding technology-transfer or commercialization deal has been disclosed after nearly 20 months. Lilly’s parallel expansions of lipid-based injectable partnerships with Camurus for overlapping peptide areas have further reduced urgency around SmartDepot. With just over two months remaining until the market resolution date and no recent announcements signaling a shift to full licensing, traders assign an 87.5% implied probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,138End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 agreement with Peptron covers only a non-exclusive, internal R&D evaluation of the SmartDepot ultrasonic spray-dried PLGA microsphere platform for selected peptides, with any commercial license explicitly optional and not guaranteed. The evaluation window, extended to a maximum of 24 months, runs through roughly October 2026, yet no binding technology-transfer or commercialization deal has been disclosed after nearly 20 months. Lilly’s parallel expansions of lipid-based injectable partnerships with Camurus for overlapping peptide areas have further reduced urgency around SmartDepot. With just over two months remaining until the market resolution date and no recent announcements signaling a shift to full licensing, traders assign an 87.5% implied probability to “No.”
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions